तुलना करने के लिए मीट्रिक्स | ORX | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधORXपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −2.0x | 59.6x | −0.4x | |
PEG अनुपात | −0.01 | −0.75 | 0.00 | |
क़ीमत/बुक | 2.3x | 5.2x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 47.7x | 4.9x | 3.0x | |
अपसाइड (विश्लेषक लक्ष्य) | 19.3% | 93.9% | 50.7% | |
उचित मूल्य अपसाइड | अनलॉक करें | −1.6% | 6.5% | अनलॉक करें |
Orexo AB (publ), a pharmaceutical company, provides advance treatments for severe diseases and life-saving rescue medications in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; Edluar for the treatment of insomnia; and Diabact UBT for the treatment of diagnosis of Helicobacter pylori. The company is developing Izipry for opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; OX390 for overdoses caused by a combination of life-threatening illicit drugs; OX125 for opioid overdose with powder-based nalmefene; OX472 for intranasal formulation of semaglutide, a GLP-1 receptor agonist, developed using proprietary AmorphOX technology; and develops thermostable and needle-free mucosal vaccines. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.